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Abstract  23 
Background: The majority of antimicrobial stewardship programmes (ASP) focus on prescribing in 24 
adult populations, however there is a recognised need for targeted paediatric antimicrobial 25 
stewardship to improve the quality and safety of prescribing amongst this patient group. 26 
Objectives: To describe the current epidemiology of antimicrobial prescribing in paediatric inpatient 27 
populations in Scotland to establish a baseline of evidence and identify priority areas for quality 28 
improvement to support a national paediatric antimicrobial stewardship programme. 29 
Methods: A total of 559 paediatric inpatients were surveyed during the Scottish national point 30 
prevalence survey of healthcare-associated infections and antimicrobial prescribing, 2016. The 31 
prevalence of antimicrobial prescribing was calculated and characteristics of antimicrobial 32 
prescribing were described as proportions and compared between specialist hospitals and paediatric 33 
wards in acute hospitals.   34 
Results: Prevalence of antimicrobial use in paediatric inpatients was 35.4% (95% CI: 31.6 to 39.4). 35 
Treatment of community and hospital-acquired infections accounted for 47.1% and 20.7% of 36 
antimicrobial use respectively, with clinical sepsis being the most common diagnosis and gentamicin 37 
the most frequently prescribed antimicrobial for the treatment of infection. The reason for 38 
prescribing was documented in the notes for 86.5% of all prescriptions and of those assessed for 39 
compliance against local policy, 92.9% were considered compliant. 40 
Conclusions: Data from national prevalence surveys are advantageous when developing 41 
antimicrobial stewardship programmes (ASP). Results have highlighted differences in the prescribing 42 
landscape between paediatric inpatient populations in specialist hospitals and acute hospitals, and 43 
have informed priorities for the National ASP which reinforces the need for a targeted paediatric 44 





Appropriate prescribing is imperative so that patients receive the optimal choice of antimicrobial to 48 
treat or prevent infection, but also to avoid unfavourable consequences of antimicrobial misuse 49 
including the emergence of multi-drug resistant pathogens, the risk of Clostridioides difficile 50 
infection and other adverse events.1;2 Antimicrobial stewardship programmes (ASP), which involve a 51 
coordinated approach to promoting and monitoring the careful use of antimicrobials to preserve 52 
their future effectiveness3, have been successful in improving antimicrobial prescribing behaviours 53 
and outcomes.1;4 54 
Until now, the majority of ASP have focused primarily on adults, however the need for a targeted 55 
ASP within paediatric populations is recognised.1 While there is evidence suggesting that prescribing 56 
within paediatric populations can often be inappropriate and with much                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  57 
variation between facilities;1;5-7 it has been demonstrated that paediatric ASP can be successful in 58 
reducing overall antimicrobial use, costs and prescribing errors. No apparent negative impact on 59 
patient safety has been demonstrated, however more studies on outcomes is required7-9 60 
This said, there are many complexities associated with paediatric antimicrobial stewardship 61 
including issues around early identification and diagnosis of a sick child.10 Signs and symptoms of 62 
infection vary greatly between newborns, infants, children and teenagers meaning that recognition 63 
and severity scoring are problematic which makes appropriate prescribing more challenging.10 64 
Moreover, for quantitative surveillance of antimicrobial use within ASP, the internationally 65 
recognised standard unit of medicine consumption, the total DDD per 1000 population per day 66 
(DDD/1000/day), is not appropriate for use within paediatric populations.11  67 
In the absence of continuous audit data, point prevalence surveys (PPS) have been used to 68 
successfully monitor the quality of antimicrobial prescribing in hospitals.12-14 The Antibiotic 69 
 
 
Resistance and Prescribing in European Children (ARPEC) study collected antimicrobial prescribing 70 
data from 17,693 paediatric patients in 226 hospitals in 41 countries worldwide using a standardised 71 
web-based prevalence methodology over one day in October and November 2012.15;16 The ARPEC 72 
study identified a prescribing prevalence of 36.7% and described the feasibility of adapting existing 73 
adult quality indicators of antimicrobial prescribing for the paediatric hospital setting, with the 74 
purpose of uniformly assessing prescribing, identifying areas of poor practice and proposing 75 
international benchmarks.16 76 
The Scottish Antimicrobial Prescribing Group (SAPG) was established in 2008 to coordinate the 77 
delivery of a national ASP to optimise antimicrobial prescribing. Using data from the Scottish 78 
national PPS, SAPG previously identified targets for national quality improvement in antimicrobial 79 
use in Scottish hospitals,13 however these stewardship efforts hitherto have focused on adult 80 
inpatients. The recent European-wide PPS of healthcare associated infection (HAI) and antimicrobial 81 
prescribing, 2016 provided a snapshot of the number and types of antimicrobials being prescribed, 82 
to whom and for which diagnosis at a single point in time. In Scotland, this survey was mandatory 83 
and conducted in all NHS acute and specialised hospitals, and therefore captured information on all 84 
hospitalised inpatients.17 Using these data, we aim to describe the current national prevalence of 85 
antimicrobial prescribing in paediatric inpatients in Scottish hospitals, to establish a baseline and 86 





A Privacy Impact Assessment was undertaken and the project was reviewed and approved by the 92 
Public Benefit and Privacy Panel for Health and Social Care (PBPP) (Application Number: 1516-0599). 93 
 
 
PBPP is a governance structure of NHS Scotland that has authority for decision-making on behalf of 94 
NHSScotland Chief Executive Officers and the Registrar General. 95 
Study design 96 
Data from the Scottish national PPS of HAI and antimicrobial prescribing, 2016 were used. These 97 
data were collected during a rolling PPS conducted from 1st September to 30th November 2016 in all 98 
acute NHS hospitals in Scotland using a standardised methodology and definitions adapted for use in 99 
Scotland17 from the ECDC protocol.18 Data were collected in each hospital within a period of one 100 
week by trained staff from local infection prevention and control, and antimicrobial management 101 
teams. Data on inpatient demographics, HAI and antimicrobial prescribing were extracted from a 102 
number of sources available on the ward at the time of survey including prescribing charts, nursing 103 
and medical notes. Full details of the study design, inclusion/exclusion criteria and case definitions 104 
are described in the survey protocol.19 105 
Data items collected and definitions  106 
This analysis was restricted to paediatric inpatients only, which were defined as patients admitted 107 
to; (1) one of the three specialist paediatric NHS hospitals in Scotland or; (2) one of 22 acute NHS 108 
hospitals (teaching, general and maternity hospitals, herein described as ‘acute’) and were (a) aged 109 
16 years and under or (b) aged 18 years and under, and under the care of a paediatric consultant. 110 
Healthy neonates were excluded from this analysis. 111 
Information on inpatient demographics, McCabe score (reflecting the underlying medical condition 112 
and based on prognosis),20 device use and specialty of care was collected for each surveyed patient. 113 
Data on systemic antibacterials (ATC J01) and antimycotics (J02) prescribed for treatment or 114 
prophylaxis were also collected. Antimycobacterials specifically for the treatment of Mycobacterium 115 
tuberculosis (J04), antivirals (J05) and topical antimicrobials were excluded.  116 
 
 
Antimicrobial prescribing prevalence was defined as the total number of paediatric inpatients 117 
receiving at least one systemic antimicrobial at the time of survey as a percentage of the total 118 
number of paediatric inpatients. The name of antimicrobial, route of administration, indication for 119 
prescribing and diagnosis were recorded for each antimicrobial. Diagnoses and indications were as 120 
recorded at the time of prescribing by the prescriber. Clindamycin, ciprofloxacin and other 121 
quinolones, co-amoxiclav and the cephalosporins were considered broad spectrum in this analysis, 122 
and the carbapenems and piperacillin/tazobactam considered very broad spectrum. 123 
Information on any change of antimicrobial during a hospital stay;  if the reason for prescribing was 124 
recorded in the notes or medicine chart and; if prescribing complied with local policy, was also 125 
collected. The percentage of antimicrobials with the reason recorded in the notes was calculated 126 
(excluding those where the patient’s case notes were not available to review). The choice of 127 
antimicrobial prescribed for empirical prescribing and surgical prophylaxis was assessed to identify if 128 
this complied with local policy, if there was one available (the route, dose and duration were not 129 
assessed). Prescribing was considered non-compliant where the reason or indication was not 130 
recorded, and if notes were not available for review then policy was recorded as ‘not known’.  131 
Using those proposed by ARPEC as a framework (Versporten et al, 2016),16 potential quality 132 
indicators of antimicrobial prescribing were also collected, including those collected as part of the 133 
ECDC protocol, and additional data to assess compliance with local policy 134 
 135 
Statistical analysis  136 
Inpatient demographics, McCabe score, device use and specialty of care were compared between 137 
hospital types using Pearson’s chi square tests with a continuity correction to provide an 138 
understanding of potential differences in prescribing patterns and the need for tailored ASP. The 139 
distribution of age between inpatients in specialist versus acute hospitals was compared using a 140 
Mann-Whitney U test. Prevalence calculations with Wilson’s 95% CI were calculated. The prescribing 141 
 
 
quality indicators in specialist and acute hospitals were compared using Pearson’s chi square tests. 142 
Analysis was carried out using R version 3.5.0. 143 
 144 
Results 145 
Survey population 146 
A total of 559 paediatric inpatients were surveyed and the demographic details are described in 147 
Table 1. Approximately one half (n=249, 44.5%) of paediatric inpatients received care in one of the 148 
three specialist paediatric hospitals, and the remainder received care within one of 22 acute 149 
hospitals.  Patients in specialist hospitals were older (p<0.001), had poorer prognoses (p<0.001), had 150 
higher use of central vascular catheters (p<0.001) and urinary catheter use (p=0.02) when compared 151 
with those in acute hospitals.  152 
 153 
Prevalence of antimicrobial use 154 
A total of 200 paediatric inpatients received 368 antimicrobials, giving an antimicrobial prescribing 155 
prevalence of 35.9% (95% CI: 32.0 to 40.0).  The prevalence of prescribing in paediatric specialist 156 
hospitals (40.7%, 95% CI: 34.8 to 46.9) was significantly higher than in acute hospitals (32.0%, 95% 157 
CI: 27.1 to 37.4) (p=0.03). 158 
 159 
Characteristics of antimicrobial prescribing 160 
Two thirds of antimicrobials prescribed were for treatment of infection. Community acquired 161 
infection (47.8%) and hospital acquired infection (20.6%) were the most frequent indications for 162 
prescribing Medical prophylaxis and surgical prophylaxis accounted for 20.9% and 1.2% of all 163 
antimicrobials prescribed, respectively. 164 
 
 
Five diagnoses accounted for over half of all antimicrobials prescribed for treatment of infection: 165 
clinical sepsis, febrile neutropaenia, intra-abdominal sepsis, bronchitis and cystic fibrosis (Table 2). 166 
The types of infections treated differed in acute and specialist hospitals with clinical sepsis and 167 
febrile neutropaenia the most common diagnoses, respectively. The overall prevalence of 168 
antimicrobial prescribing for the treatment of clinical sepsis among all paediatric inpatients was 4.8% 169 
(95% CI: 3.4 to 7.0). There were 27 paediatric inpatients receiving 36 antimicrobials for general 170 
medical prophylaxis of unspecified anatomical site, e.g. medical prophylaxis in haematology patients, 171 
which was the most frequently recorded reason. Four inpatients received a total of four 172 
antimicrobials for surgical prophylaxis.  173 
The distribution of antimicrobial agents, by indication, is shown in Figure 1. Gentamicin was the 174 
most frequently prescribed antimicrobial for the treatment of infection (15.8%), and ten different 175 
antimicrobial types accounted for more than three quarters of all treatment antimicrobials 176 
prescribed. Co-trimoxazole was the most commonly prescribed antimicrobial for medical prophylaxis 177 
(23.2%). Very broad spectrum antimicrobials accounted for 9.0% of all antimicrobials prescribed. 178 
This was higher in specialist paediatric hospitals than acute hospitals (12.4% versus 5.5%, p=0.02). 179 
Broad spectrum antimicrobials, commonly associated with Clostridioides difficile infection, 180 
accounted for one in five antimicrobials prescribed and there was no significant difference between 181 
specialist and acute hospitals.   182 
Three quarters of antimicrobials were administered via the parenteral route, with clinical sepsis and 183 
intra-abdominal sepsis being the most common diagnoses treated parenterally. More than a third 184 
(35.5%) of parenteral antimicrobials had been given for longer than three days at the time of the 185 
survey. Two fifths of oral antimicrobials had been given for more than seven days at the the time of 186 
survey (n=36, 40.0%).  187 
Of the 368 antimicrobials prescribed to paediatric inpatients, the antimicrobial agent or route of 188 
administration was changed and the reason for change documented for 54 antimicrobials. The 189 
 
 
reasons for change included: escalation of therapy for 55.6% of antimicrobials (n=30), intravenous to 190 
oral switch for 20.4% of antimicrobials (n=11), and de-escalation for 11.1% of antimicrobials (n=6). 191 
The reason for change of the remainder was described as ‘other’. 192 
The reason for prescribing was documented in the notes for 85.8% (n= 307) of all prescriptions and 193 
for 68.9% and 91.8% of prophylactic and treatment antimicrobials, respectively. For antimicrobials 194 
assessed for compliance with local policy, 92.1% were considered compliant. This was 100.0% and 195 
92.0% for surgical prophylaxis (n=2) and treatment (n=163) respectively, and 86.8% and 95.9% in 196 
paediatric specialist and acute hospitals, respectively. 197 
Antimicrobial prescribing quality indicators adapted for Scotland from those suggested by ARPEC, 198 
are described in Table 3. The percentage of antimicrobials where the reason for prescribing was 199 
documented and compliance with local policy were higher in the acute hospitals compared with the 200 
specialist hospitals (p<0.001 and p=0.03, respectively).  201 
 202 
 203 




This study is, as far as we know, the first comprehensive national point prevalence survey of 206 
antimicrobial prescribing and antimicrobial indicators in all hospitalised paediatric patients at the 207 
national level. These data provide the baseline to inform the establishment of a national paediatric 208 
antimicrobial stewardship programme.   209 
 210 
Our findings estimate that around one in every three hospitalised paediatric patients in Scotland 211 
receive antimicrobial treatment. While the prevalence of antimicrobial prescribing is similar to that 212 
in adults in acute hospitals in Scotland17 the prescribing landscape differs. For example, 213 
approximately one fifth of treatment antimicrobials prescribed in paediatric populations was for a 214 
diagnosis of clinical sepsis whereas by contrast, this accounted for only 2.9% of the treatment 215 
antimicrobials prescribed to adults in acute hospitals. Similarly, approximately one in every five 216 
antimicrobials prescribed to paediatric patients were for medical prophylaxis, but in the adult 217 
population this figure was one in twenty. These are important differences that justify the need for a 218 
targeted paediatric ASP. The high prevalence of clinical sepsis highlights the importance of severity 219 
scoring and use of prognostic indicators in paediatric inpatients. This is important in the context of 220 
fewer community-acquired sepsis cases due to improved immunisation schedules. Since the 221 
recognition of clinical sepsis in children can often be challenging and their response to treatment 222 
variable, regular clinical reviews should feature as a key part of stewardship activities. 223 
 224 
We found differences between acute hospitals and specialist hospitals which may reflect that 225 
alongside other local improvement initiatives, the Scottish national antimicrobial stewardship 226 
programme may be having a broader influence than where it has been targeted in acute adult 227 
inpatient populations. We found that the reason for prescribing was documented for 86.5% of all 228 
prescribed antimicrobials although this varied by indication (72.6% and 91.8% for prophylaxis and 229 
 
 
treatment antimicrobials, respectively) and hospital type (79.9% and 92.3% for specialist and acute 230 
hospitals, respectively). Documenting the reason for prescribing in patient notes is important to 231 
ensure that all health professionals involved in giving care to a patient are aware of the current and 232 
historical clinical and prescribing picture.16 While this level of documentation is encouraging 233 
considering that national interventions have focused on adult populations, these data highlight a 234 
potential area for improvement, particularly around medical prophylaxis. 235 
 236 
Similarly we found compliance with local policy in paediatric patients in acute hospitals was higher 237 
than in specialist hospitals (95.9% versus 86.8%). Compliance with local prescribing policies is a key 238 
feature of ASP and ensures that prescribing is evidence-based and takes account of local 239 
antimicrobial resistance patterns. This suggests that a more individualised approach to antimicrobial 240 
therapy is used in specialist hospitals, which may be driven by differences in staffing and expertise. 241 
Further work is required to better understand the reasons for non-compliance in these hospitals. 242 
There were a number of differences with respect to the paediatric population and antimicrobial 243 
prescribing patterns between specialist hospitals and paediatric wards within acute hospitals. 244 
Patients in specialist hospitals require more specialised care and therefore different stewardship 245 
activities may need to be considered depending on the hospital setting.  246 
 247 
Three quarters of antimicrobials were administered via the parenteral route and more than a third 248 
of these were administered for longer than three days at the time of survey. Parenterally 249 
administered antimicrobials are commonly employed in paediatrics as unwell and particularly 250 
younger children are often unable to tolerate oral antimicrobials. However, a key stewardship 251 
intervention is the regular review of patients prescribed parenteral antimicrobials to consider 252 




One in every six antimicrobials prescribed to paediatric patients was considered to be broad 255 
spectrum and one in every 12 was very broad spectrum. The use of broad spectrum antimicrobials is 256 
associated with an increased risk of Clostridioides difficile infection (CDI) and reducing inappropriate 257 
use of these agents continues to be a priority. In addition, many of the antimicrobial agents 258 
considered broad and very broad spectrum including carbapenems, piperacillin/tazobactam, third 259 
generation cephalosporins, macrolides and quinolones are on the World Health Organisation’s 260 
‘watch’ list due to concerns over higher toxicity and antimicrobial resistance potential.2 Their use 261 
should be restricted to preserve their activity and only prescribed on specialist advice with the 262 
ongoing need for them be reviewed on a daily basis.  263 
 264 
Strengths and limitations  265 
A key strength of this analysis is that the PPS included all NHS hospitals in Scotland thereby giving a 266 
complete national picture of prescribing in the paediatric inpatient population. Additionally, the 267 
protocol and case definitions used were evidence-based and internationally agreed giving 268 
comparability and methodological rigour. Limitations of all prevalence surveys are that they 269 
represent a snapshot of prescribing at one point in time which may not represent prescribing at 270 
other times, trends cannot be measured and causality cannot be inferred. Furthermore, the survey 271 
included 559 paediatric inpatients however, due to missing information for some data items, not all 272 
inpatients could be included in denominators when calculating prevalence estimates or percentages.  273 
 274 
Conclusion 275 
The availability of current data and quality indicators from a national prevalence survey that includes 276 
the whole population is an advantage when priority setting and developing antimicrobial 277 
stewardship programmes. In this study we investigated patterns of antimicrobial use and described 278 
potential quality indicators that provide baseline information on antimicrobial use in paediatric 279 
populations. We demonstrated differences in AM use between acute and specialist hospitals and, 280 
 
 
SAPG as part of the national paediatric ASP is addressing the variation through development of 281 
national consensus guidelines. We will utilise experience in specialist hospitals to optimise 282 
management of common infections in children across all settings. Additional key clinical priority 283 
areas include working with patient safety partners to improve recognition of sepsis in young children 284 
and consideration for the implementation of quality imrovement toolkit to support review of 285 
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Table 1: Characteristics of the paediatric inpatient population, 2016 
 Paediatric inpatients in 
acute hospitals 
Paediatric inpatients in 
specialist hospitals 
All paediatric inpatients 
 Number of patients n = 310 n = 249 n = 559 
Age 
Median age 
1 month (range 0 months 
to 17 years, IQR = 0 
months to 21 months) 
24 months (range 0 months 
to 18 years, IQR = 0 months 
to 9 years) 
5 months (range 0 months to 18 
years, IQR = 0 months to 5 years) 
% aged < 1 year 71.6% 34.1% 54.9% 
% aged < 1 month 42.6% 12.0% 29.0% 
Sex % female 45.8% 44.2% 45.1% 
Prognosis % with most severe McCabe Scores 8.6% 20.5% 14.1% 
Devices 
% with CVC in situ 6.1% 27.3% 15.6% 
% with PVC in situ 33.8% 40.1% 36.6% 
% with urinary catheter in situ 1.0% 4.5% 2.5% 
% with intubation 5.8% 9.3% 7.4% 
Specialties Three most common specialties 
Paediatric Neonatology 
(other than NICU) (35.8%) 
 
General Medicine (14.9%) 
Paediatric Neonatology (other 
than NICU) (23.1%) 
ICU Neonatal (27.1%) ICU Neonatal (10.8%) and 
ICU Paediatric (10.8%) 
ICU Neonatal (19.9%) 
General Medicine (14.2%) General Surgery (Excluding 
vascular) (8.4%) 














Paediatric inpatients in 
acute hospitals 
Paediatric inpatients in 
specialist hospitals 
All paediatric inpatients 
N % N % N % 
Clinical sepsis (suspected BSI without lab confirmation), excluding febrile neutropaenia  39 31.5 11 9.7 50 21.1 
Febrile neutropaenia  0 0.0 22 19.5 22 9.3 
Intra-abdominal sepsis (including hepatobiliary)  12 9.7 9 8.0 21 8.9 
Acute bronchitis or exacerbations of chronic bronchitis  7 5.7 10 8.9 17 7.2 
Cystic fibrosis  5 4.0 12 10.6 17 7.2 
Pneumonia  8 6.5 7 6.2 15 6.3 
Cellulitis, wound, deep soft tissue not involving bone  13 10.5 2 1.8 15 6.3 
Infections of ear, nose, throat, larynx and mouth  9 7.3 6 5.3 15 6.3 
Symptomatic upper urinary tract infection  7 5.7 6 5.3 13 5.5 
Infections of the central nervous system  7 5.7 6 5.3 13 5.5 
Laboratory confirmed bacteraemia  3 2.4 9 8.0 12 5.1 
Systemic inflammatory response with no clear anatomic site  7 5.7 4 3.5 11 4.6 
Symptomatic lower urinary tract infection  2 1.6 3 2.7 5 2.1 
Surgical site infection involving skin or soft tissue but not bone  1 0.8 3 2.7 4 1.7 
Septic arthritis (including prosthetic joint), osteomyelitis  2 1.6 0 0.0 2 0.8 
Gastrointestinal infections  0 0.0 2 1.8 2 0.8 
Gynaecological infections  1 0.8 0 0.0 1 0.4 
Not recorded  1 0.8 1 0.9 2 0.8 








Table 3: Comparison of quality indicators of antimicrobial prescribing in hospitalised paediatric populations between acute and specialist, 2016 










Comparison of prescribing 
indicators in paediatric wards in 
acute hospitals with prescribing 
in specialist paediatric hospitals 




n= 368 antimicrobials 
Documentation of the reason for antimicrobial 







Percentage of all antimicrobials prescribed that 
were compliant with local policy (empirical 







Percentage of all antimicrobials prescribed that 





p<0.001 73.4%  
(n=265) 
Percentage of patients receiving antimicrobials that 





p=0.02 58.5%  
(n=117) 
Percentage of all antimicrobials prescribed that 
were broad spectrum or very broad spectrum 
BS: 15.3% (n=28) 
 
VBS: 5.5% (n=10) 
BS: 20.5% (n=38) 
 




BS: 17.9% (n=66) 
 
VBS: 9.0% (n=33) 
Antimicrobial prescribing prevalence for hospital-
acquired infections (excluding healthy neonates) 
8.1%  
(95% CI: 5.5 to 11.7) 
(n=25) 
6.0%  
(95% CI: 3.7 to 9.7) 
(n=15) 
p=0.35 7.2% 
(95% CI: 5.3 to 9.6) 
(n=40) 
Percentage of  antimicrobials prescribed to treat 
hospital-acquired infections* that were broad 
spectrum or very broad spectrum  
BS: 4.9% (n=2) 
 
VBS: 17.1% (n=7) 
BS: 3.3% (n=1) 
 




BS: 4.2% (n=3) 
 
VBS: 18.3% (n=13) 
Percentage of antimicrobials prescribed to treat 
community-acquired infections* that were broad 
spectrum or very broad spectrum  
BS: 26.8% (n=22) 
 
VBS: 1.2% (n=1) 
BS: 27.7% (n=23) 
 




BS: 27.3% (n=45) 
 
VBS: 10.3% (n=17) 
Notes: *All percentages exclude records with missing information from denominator. BS: Broad spectrum antimicrobials - clindamycin, ciprofloxacin and other quinolones, 
co-amoxiclav and the cephalosporins; VBS: Very broad spectrum - carbapenems and piperacillin/tazobactam  
